A mixed performance in the stock price over the year has left investors with either an optimistic or pessimistic outlook, depending on their point of view. Until today this year the stock’s price performance recorded an increase of 22.40%. However, over the last six months, the performance has been weaker by 97.76%. The price of PBYI decreased -19.70% over the last 30 days. And in the last five days, it has fallen by -0.93%.
In terms of market performance, Puma Biotechnology Inc had a fairly even. The highest value for the stock in the past year was $7.73 on 02/15/24, and the lowest value was recorded at $2.13 on 10/25/23.
52-week price history of PBYI Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Puma Biotechnology Inc’s current trading price is -31.44% away from its 52-week high, while its distance from the 52-week low is 148.83%. The stock’s price range during this period has varied between$2.13 and $7.73. The Puma Biotechnology Inc’s shares, which operate in the Healthcare, saw a trading volume of around 0.28 million for the day, a figure considerably lower than their average daily volume of 0.62 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Puma Biotechnology Inc (PBYI) has experienced a quarterly rise of 22.12% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 255.51M and boasts a workforce of 185 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 4.79, with a change in price of +2.81. Similarly, Puma Biotechnology Inc recorded 501,936 in trading volume during the last 100 days, posting a change of +112.85%.
PBYI’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for PBYI stands at 2.09. Similarly, the long-term debt-to-equity ratio is also 1.36.
PBYI Stock Stochastic Average
As of today, Puma Biotechnology Inc’s raw stochastic average for the last 50 days stands at 32.31%. This is a decline compared to the raw stochastic average of the previous 20 days, which was noted at 58.59%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 51.64% and 48.41%, respectively.
